PREVEND IT – Prevention of Renal and Vascular Endstage Disease Intervention Trial
Principal contacts
Frank P. J. Brouwers - Haga Teaching Hospital, the Hague, the Netherlands
Folkert W. Asselbergs - University Medical Center Utrecht, Utrecht, the Netherlands
Wiek van Gilst - University Medical Center Groningen, Groningen, the Netherlands
Study design
The Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) is a clinical trial with a 2×2 factorial design, a substudy of the PREVEND program, and is based in Groningen, the Netherlands. The principal aim of the trial was to investigate the effect of Fosinopril (20mg/day) or Pravastatin (40mg/day) on cardiovascular and renal disease in non-hypertensive and non-hypercholesterolaemic individuals. All inhabitants of the city of Groningen were eligible for inclusion if they were aged between 28 and 75 years with persistent microalbuminuria, no hypertension, and no hypercholesterolaemia. The study was approved by the Institutional Review Board. Informed consent was obtained from all subjects before randomization.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT03073018
Key publications
Rationale, Design, and Baseline Characteristics of a Trial of Prevention of Cardiovascular and Renal Disease With Fosinopril and Pravastatin in Nonhypertensive, Nonhypercholesterolemic Subjects With Microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol. 2000 Sep 15;86(6):635-8
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. Circulation. 2004 Nov 2;110(18):2809-16
Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria. Stroke. 2005 Mar;36(3):649-53
Cost-Effectiveness of Screening for Albuminuria with Subsequent Fosinopril Treatment to Prevent Cardiovascular Events: A Pharmacoeconomic Analysis Linked to the Prevention of REnal and Vascular ENdstage Disease (PREVEND) Study and the Prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT). Clin Ther. 2006 Mar;28(3):432-44
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J. 2011 Jun;161(6):1171-8